Condition
Patent Ductus Arteriosus (PDA)
Total Trials
6
Recruiting
0
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 2 (2)
Trial Status
Completed2
Not Yet Recruiting1
Enrolling By Invitation1
Active Not Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06587282Not ApplicableActive Not RecruitingPrimary
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT07067177Phase 2Enrolling By Invitation
Prophylactic IV Paracetamol in Extremely Premature Infants
NCT06634407Not ApplicableNot Yet RecruitingPrimary
Outcome of Transcatheter Closure of Patent Ductus Arteriosus in Pediatric Cardiology Unit in 3 Years Duration
NCT00583596Not ApplicableCompletedPrimary
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
NCT02100683CompletedPrimary
Nit-Occlud PDA Post-Approval Study
NCT02620761Phase 2TerminatedPrimary
Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants
Showing all 6 trials